Optimizing Antibody Development for Cancer Treatment
Author Information
Author(s): Gregor Rossmueller, Irina Mirkina, Michael Thiele, Alejandro Puchol Tarazona, Florian Rueker, Randolf J. Kerschbaumer, Alexander Schinagl
Primary Institution: OncoOne Research & Development GmbH
Hypothesis
Can combining in silico tools with in vitro assessments improve the properties of therapeutic antibodies?
Conclusion
The study successfully engineered a second-generation anti-oxMIF antibody, C0083, which showed improved biophysical properties and pharmacokinetics compared to the first-generation antibody, imalumab.
Supporting Evidence
- The engineered antibody C0083 showed a 1.4-fold longer half-life compared to imalumab.
- C0083 demonstrated significantly reduced hydrophobicity and aggregation potential.
- Mutations introduced did not affect the binding affinity to the target, oxMIF.
- Structural analysis revealed that the mutations led to a reorganization of the antibody's CDR3 loop.
Takeaway
Scientists made a better version of an antibody that helps treat cancer by changing a few tiny parts of it, making it work better in the body.
Methodology
The study combined computational modeling with experimental validation to identify and implement mutations in the antibody's structure.
Limitations
The study primarily focused on a single antibody and may not generalize to all therapeutic antibodies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website